A portfolio strategy is a necessity for a life sciences company dealing with multiple inline and pipeline assets to ensure optimal positioning combined with effective resource allocation to drive results. Developing the right portfolio strategy is critical to ensure that company goals are achieved. Our streamlined approach allows R&D and Commercial groups to assess gaps in the current portfolio and develop potential options to address these gaps.
With tight R&D budgets and high failure rates in product development, prioritizing product portfolios is critical for any company. An objective process is required to assess, prioritize, and allocate resources across these R&D projects. A portfolio prioritization process/system based on key scientific and commercial metrics is needed to effectively prioritize products. An integrated strategy across R&D, Business Development and Commercial is often required to achieve portfolio goals.
Other Areas of portfolio management Expertise
- Standardized Asset Valuations
- Structured Portfolio Management Approach
- Establishing Objective Criteria
- Standardized Scoring
- Portfolio Management Tool Development
- Corporate Governance & Implementation
- Strategic Portfolio Evaluations
- Asset Valuation
- Asset Prioritization
New Product Strategy
Target Value Profile
One of the most important tools to help ensure successful product development and commercialization is a well-planned Target Value Profile (TVP). A successful TVP development requires an understanding of today’s disease/treatment/market dynamics and as well as how these dynamics will change at the time of launch which is typically several years away. We leverage our proven TVP process to engage appropriate functional areas to effectively address clinical, regulatory and market needs. A key to successful TVP development is to begin early and ensure cross functional participation. This TVP combined with a clinical strategy allows companies to effectively plan and execute product development activities.
Other Areas of New Product Planning Expertise
- Cross-Functional Product Assessments
- Third Party Due Diligence
- Draft Launch Label
- Preliminary Positioning
- Early Market Planning
- Patient Treatment Flow Models
- Scenario Planning
Life Cycle Planning
LCM strategies range from new indications to end of life cycle Rx to OTC switching strategies. The evidence supporting these strategies is typically generated through phase IIIb, phase IV, and research studies and the outcomes require regulatory approval prior to commercializing these opportunities. Multivariate strategies can be adopted depending on the life cycle stage of the product and the availability of resources. LCM strategies, if successful, can offer new solutions, create switching costs, and increase the lifetime value of the product. The following are the most common LCM strategies to create incremental value for the product.
OTHER AREAS OF Life Cycle Planning EXPERTISE
- Strategic Assessment
- Life Cycle Concept Development
- C/F Opportunity Assessment
- Prioritizing Options
- Market Testing / Valuation
- Decision Making & Implementing Plans
- CRTC Assessment